# Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors

> **NCT02168725** · PHASE1 · TERMINATED · sponsor: **Traws Pharma, Inc.** · enrollment: 26 (actual)

## Conditions studied

- Neoplasms
- Advanced Solid Tumor

## Interventions

- **DRUG:** briciclib

## Key facts

- **NCT ID:** NCT02168725
- **Lead sponsor:** Traws Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-06
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 26 (ACTUAL)
- **Why stopped:** The study was placed on hold by the FDA due to manufacturing issues and was not restarted.
- **Last updated:** 2021-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02168725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02168725, "Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02168725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*